ArticleEuropean radiology2026
Outcomes following microwave ablation of 669 primary and metastatic lung malignancies.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Thermal ablation of lung metastases in children: what every paediatric radiologist should know.Pediatric radiology · 2026Review
- Quantitative analysis of lung microwave ablation zone volume and shape.European radiology experimental · 2026Article
- Automated Deformable Registration and Three-dimensional Margin Assessment for Predicting Local Recurrence after Lung Thermal Ablation.Radiology. Imaging cancer · 2026Article
- Advances in Percutaneous and Endovascular Locoregional Therapies for Primary and Metastatic Lung Cancer.Cancers · 2026Review
- CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management.Translational oncology · 2026Article
- Risk factors and immune landscape of early local tumor progression after microwave ablation for lung cancer: a retrospective nested case-control study.Frontiers in immunology · 2026Article
- Transarterial infusion chemotherapy combined with microwave ablation for inoperable triple-negative breast cancer: a case report.Frontiers in oncology · 2026Article
- Shape-Sensing Robotic-Assisted Bronchoscopic Microwave Ablation for Primary and Metastatic Pulmonary Nodules: Retrospective Case Series.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
objectivesPercutaneous ablation is a treatment modality used in the management of primary and metastatic lung malignancies. Factors affecting local control rate (LCR) following microwave ablation (MWA) are poorly understood due to inconsistent and limited reporting of histology and procedure-related outcomes. MATERIALS AND
methodsSingle-center retrospective study of patients with primary and metastatic lung malignancies who underwent MWA between January 2010 and July 2021. Patient, tumor and ablation characteristics were recorded. Outcomes evaluated included technical success, local tumor control and adverse events (AEs).
resultsA total of 669 nodules were identified from 383 patients (197 male/186 female with a median age of 59 years (IQR = 21 years)) across 459 ablation sessions. This comprised 83 primary and 586 metastatic lung tumors. One-year and two-year local LCRs (±SD) across the cohort were 90.3% (±1.1%) and 84.7% (±1.4%), respectively. Multivariable analysis identified ablation power settings, age, concomitant chemotherapy and histology as significant covariates associated with time to local recurrence (TTLR). Standard power was associated with longer TTLR, compared to low power, with no significant difference in AE rates. A significant difference in TTLR was noted between different histological groups.
conclusionMWA of primary and metastatic lung tumors is safe and effective. LCRs differ across different histologies. Standard power MWA is associated with longer TTLR without increased AEs rates. KEY POINTS: Question Reported local control rates for microwave ablation (MWA) vary widely, with limited and heterogeneous data on histology-specific and parameter-related outcomes, leaving a gap in understanding. Findings MWA achieved 90.3% and 84.7% one- and two-year local control rates, with longer time to recurrence for standard power MWA. Histology-specific differences noted in time to recurrence. Clinical relevance MWA is a safe and effective treatment for primary and secondary lung cancers, offering comparable local control rates to radiotherapy and surgical resection. Further refinement of treatment parameters may enhance outcomes and address histology-specific challenges.
Indexed as
Identifiers
40960505What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.